Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Key Terms
adjusted ebitdafinancial
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
adjusted earnings per sharefinancial
Adjusted Earnings Per Share shows how much profit a company makes for each share of stock, but it removes unusual or one-time items like big expenses or gains. This helps investors see the company's true ongoing performance, making it easier to compare how well different companies are doing over time.
forward-looking statementsregulatory
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
non-gaap financial measuresfinancial
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
gaapfinancial
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
form 8-kregulatory
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
exhibit 99.1regulatory
Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.
Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S.
IRVINE, Calif.--(BUSINESS WIRE)--
Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.
CLIA Waived CitoCBC System Designed for On-Site Testing in Urgent Care Centers and Physician Offices.
“We are pleased to join with CytoChip to provide the CitoCBC system to our customers, helping to bring essential lab testing out of the hospital and into the office, with results provided to the patient during their visit,” said Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical. “This collaboration strengthens our commitment to offering healthcare providers products and solutions that increase efficiencies while enhancing patient care.”
The CitoCBC system delivers full CBC results in approximately eight minutes, requires minimal staff training, and provides lab-quality accuracy by miniaturizing advanced fluorescent flow cytometry technology onto a cartridge for use in near-patient settings.
“Partnering with Henry Schein enables us to expand the reach of CitoCBC, assisting healthcare providers in settings such as physician offices, urgent care centers, and pharmacies to access immediate diagnostic data,” said Wendian Shi, PhD, Chief Executive Officer of CytoChip. “Together, we can support more informed diagnostic decisions and improve patients’ access to timely care.”
Henry Schein’s exclusivity in the United States includes ambulatory care settings such as physician offices, urgent care centers, as well as critical access hospitals with 25 patient beds or fewer. The exclusivity does not include long-term care or acute care facilities.
CytoChip Inc. is a diagnostic technology company founded in 2016 by researchers from Caltech and other leading institutions. Headquartered in Irvine, California, the company is dedicated to supporting healthcare providers with data-driven diagnostic solutions designed for near-patient use.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.
